

Assessing the Economic Benefit of Mass COVID-19 Vaccination Program in Iran: A Real-World Modeling Study

Hamidreza Jamaati, Saeed Karimi, Yunes Panahi, Shahnam Arshi, Maryam Hajimoradi, Fatemeh Sadat Hosseini-Baharanchi, Fariba Ghorbani, Seyed Mohsen Zahraei, Fatemeh Nouri, Ali Akbari Sari, Mahshad Goharimehr, Abdolreza Mohamadnia, Payam Tabarsi, Farzaneh Dastan, Babak Sharif-Kashani, Majid Marjani, Farin Rashid Farokhi, Seyed Mohammad Reza Hashemian, Mostafa Noorzadeh, Mojtaba Nouhi, Katayoun Tayeri, Sima Noorali, Farnaz Ahmadi, Makan Sadr, Azadeh Moradkhani, Mahdi Ahmadinia, Bahamin Astani, Rajabali Daroudi, Shadi Shafaghi

DOI: <https://doi.org/10.34172/ijhpm.8852>

Article History:

Received Date: November 10, 2024


Accepted Date: August 31, 2025

epublished Author Accepted Version: September 6, 2025

Copyright: © 2025 The Author(s); Published by Kerman University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution License (<https://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Please cite this article as: Jamaati H, Karimi S, Panahi Y, et al. Assessing the economic benefit of mass COVID-19 vaccination program in Iran: A real-world modeling study. 2025; x(x):x-x. doi: 10.34172/ijhpm.8852

This PDF file is an Author Accepted Manuscript (AAM) version, which has not been typeset or copyedited, but has been peer reviewed. IJHPM publishes the AAM version of all accepted manuscripts upon acceptance to reach fast visibility. During the proofing process, errors may be discovered (by the author/s or editorial office) that could affect the content, and we will correct those in the final proof.



Assessing the Economic Benefit of Mass COVID-19 Vaccination Program in Iran: A Real-World Modeling Study

Hamidreza Jamaati¹, Saeed Karimi², Yunes Panahi³, Shahnam Arshi⁴, Maryam Hajimoradi⁵, Fatemeh Sadat Hosseini-Baharanchi⁶, Fariba Ghorbani⁷, Seyed Mohsen Zahraei⁴, Fatemeh Nouri⁵, Ali Akbari Sari⁸, Mahshad Goharimehr⁸, Abdolreza Mohamadnia¹, Payam Tabarsi⁹, Farzaneh Dastan¹, Babak Sharif-Kashani¹⁰, Majid Marjani⁹, Farin Rashid Farokhi¹¹, Seyed Mohammad Reza Hashemian¹, Mostafa Noorizadeh^{12,13}, Mojtaba Nouhi¹⁴, Katayoun Tayeri⁴, Sima Noorali⁵, Farnaz Ahmadi⁵, Makan Sadr¹⁵, Azadeh Moradkhani¹, Mahdi Ahmadiania⁵, Bahamin Astani⁵, Rajabali Daroudi^{8*}, Shadi Shafaghi^{5*}

1. Chronic Respiratory Disease Research Center, National Research Institute of Tuberculosis and Lung Disease, Shahid Beheshti University of Medical Science, Tehran, Iran
2. Department of Ophthalmology, Torfeh Medical Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
3. Chemical Injuries Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran
4. Center for Communicable Disease Control, Ministry of Health and Medical Education, Tehran, Iran
5. Lung Transplantation Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran
6. Department of Biostatistics, School of Public Health, Iran University of Medical Sciences, Tehran, Iran
7. Tracheal Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran
8. Department of Health Management, Policy and Economics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
9. Clinical Tuberculosis and Epidemiology Research Center, National Research Institute for Tuberculosis and Lung Disease (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran
10. Department of Cardiology, Lung Transplantation Research Center, National Research Institute of Tuberculosis and Lung Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran
11. Chronic Kidney Disease Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
12. Department of Pharmaceutical Biotechnology, Faculty of Pharmacy, Bulent Ecevit University, Zonguldak, Turkey
13. Department of Biotechnology, Islamic Azad University of Medical Science, Tehran, Iran
14. National Institute for Health Research, Tehran University of Medical Sciences, Tehran, Iran
15. Virology Research Center, National Research Institute of Tuberculosis and Lung Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Correspondence to: Rajabali Daroudi; rdaoudi@yahoo.com & Shadi Shafaghi; shafaghishadi@yahoo.com

Abstract

Background: The global challenges posed by COVID-19 vaccinations require careful consideration by decision-makers at both the global and national levels, particularly in developing countries. This study aimed to evaluate the health and economic implications of implementing vaccination programs.

Methods: Two scenarios, one involving vaccination and the other without, were analyzed using the Markov Susceptible-Infectious-Recovered (SIR) model. For the vaccination scenario, real-world data, such as age-specific vaccination coverage, hospitalization rates, and mortality, were obtained from the Medical Care Monitoring Center (MCMC) and national COVID-19 registry during the Omicron wave in Iran. For the counterfactual non-vaccination scenario, we relied on model-based assumptions using published literature and expert input to estimate infection rates and clinical outcomes in the absence of vaccination. The Incremental Cost-Effectiveness Ratio (ICER) of the COVID-19 vaccination program was calculated by comparing the incremental cost per unit of Quality-Adjusted Life Year (QALY) generated to a willingness-to-pay threshold (WTP) equivalent to 1 time the Gross Domestic Product (GDP) per capita, approximately \$4091 US. One-way sensitivity analysis was conducted to ensure the reliability of the results.

Results: Overall, 2098495 extra QALYs were generated by vaccination, incurring a total extra cost of \$853.78 million. The vaccination program resulted in an average of 0.035 incremental QALYs at an additional cost of \$14.08 per person. The average ICER for adult vaccination was \$ 406.85 per QALY, indicating that it is a highly cost-effective strategy compared to non-vaccination across all age groups. Vaccinating elderly individuals proved to be the most cost-effective approach among all age categories.

Conclusion: The integrated Markov-SIR model used in this study provides valuable insights into both the health and economic impact of the COVID-19 vaccination program in Iran. These findings support the implementation of vaccination strategies and provide a framework for decision-makers to consider when formulating policies.

Keywords: Cost-Effectiveness; Incremental Cost-Effectiveness Ratio; Vaccination; COVID-19; Quality-Adjusted Life Year (QALY)

Key Messages:

Implications for Policy Makers:

- A key component of decision-making, as well as the execution, assessment, and oversight of public policies, is cost-effectiveness analysis.
- Comparing the vaccination strategy to no vaccination, our findings showed that it significantly decreased the incidence of infections, hospitalizations, intensive care unit admissions, and deaths among adults of all ages.
- By raising some additional expenses, expanding the vaccination strategy to eligible individuals would result in a significant increase in QALYs, making it cost-effective.
- Consequently, the COVID-19 vaccination program in Iran was both extremely cost-effective and beneficial to health.

Implications for Public:

The cost-effectiveness of Iran's COVID-19 mass vaccination program during the Omicron era was assessed in this study. A tool that articulates scientific knowledge, empirical evidence, and public policy in a framework for interaction with users, analysts, and decision-makers is our model for evaluating the impact of COVID-19 vaccination strategies. The most economical strategy across all age groups was determined to be immunizing the elderly. In Iran, the COVID-19 vaccination program has been both health-promoting and extremely cost-effective. Therefore, it would be cost-effective to extend the vaccination strategy to eligible individuals, as this would result in a significant increase in QALYs while incurring some additional costs.

1. Introduction

In November 2019, the severe acute respiratory syndrome coronavirus 2 caused the novel coronavirus disease 2019 (COVID-19), which was officially designated as a public health emergency with international ramifications by the World Health Organization (WHO) 2 months later ¹. As of April 2023, there have been over 762 million confirmed cases worldwide, resulting in a significant mortality rate of more than 6.8 million people since its initial appearance. ² The advent of COVID-19 has been compared to the economic conditions during World War II, which pervaded every aspect of human existence, caused economic fallout, and generated mounting strain on health budgets.^{1,3,4} The solution to effectively reducing the dissemination of COVID-19 was attributed to its vaccine as the ultimate cure.^{4,5} Therefore, there was a major necessity to speed up the development of vaccines at an unparalleled pace and scope. ⁵ Authorized vaccines differ in terms of expenses, cold-storage exigencies, clinical

effectiveness, and safety characteristics. Consequently, national authorities must choose the most applicable vaccine(s), contingent upon their respective country profiles, outbreak status, and immunization approach. ⁶

Iran's vaccination program was officially initiated on February 9, 2021, to protect public health and eventually facilitate the resumption of societal engagements. Iranian residents were able to access vaccines at no cost and were obligated to receive 2 doses of the same vaccine. As of February 2023, a majority of Iranian inhabitants (77.58%) had undergone the initial dose of vaccination, whereas 69.7% received the second dose.²

Ensuring adequate allocation of limited financial resources is mandatory for the successful implementation of vaccination strategies, particularly in such circumstances that require immunizing a critical number of individuals, which requires a significant financial scale of finance.^{4,7} Cost-effectiveness analysis is presumed to be a pivotal gateway measure that influences the decision-making process. ⁸ In unprecedented circumstances, such as COVID-19, where the availability of accurate data is uncertain and decision-making is time-sensitive, mathematical models may be utilized to estimate the health and economic consequences of healthcare interventions, providing a comprehensive and pragmatic approach. However, in such an emergency, the uncertainty related to the estimated health and economic effects of interventions is high due to the low level of available evidence. Over time, more reliable evidence has been provided regarding the effectiveness and cost of COVID-19 interventions; in addition, there is also real-world evidence regarding these interventions. Therefore, the consequences of COVID-19 interventions, such as vaccination, can be estimated more accurately. In recent years, the use of real-world evidence in the economic evaluation of health interventions has increased. ⁹

In low- and middle-income countries (LMICs), it is crucial to realize the immediate and prolonged impacts of implementing interventions on national budgets to ensure the program's long-term viability.⁸ The strategic group of experts on immunization established by the WHO has presented a roadmap intended to guide countries toward prioritizing the distribution of limited doses of immunization, which have predominantly concentrated on many contexts, while less attention has been directed toward LMIC settings.^{10,11} The present study aimed to estimate the health and economic consequences of administering COVID-19 vaccinations in Iran using decision-analytic modeling and real-world data. The findings of this study will help policy-makers evaluate the effects of the COVID-19 vaccination program after its implementation, and can also be useful in the context of LMIC countries ^{10,11}. This study addresses the scarcity of context-specific economic evaluations of COVID-19 vaccination in

the Middle East, particularly in Iran, by using national registry data to model real-world age-stratified outcomes and inform resource allocation in low-resource settings.

2. Method

2.1. Study design


To estimate the economic value of a COVID-19 vaccination program in Iran, we developed a Markov model that divided the population into 6 age groups: 18-24, 25-34, 35-44, 45-54, 55-64, and 64+ years. We applied a Markov-based Susceptible-Infectious-Recovered (SIR) framework that integrates epidemiological progression with economic evaluation components such as healthcare costs, productivity losses, and quality-adjusted life years (QALYs). This combined structure enabled a comprehensive cost-effectiveness analysis of COVID-19 vaccination strategies. The evaluation of the program's overall economic value considered both medical and nonmedical costs, such as medical treatment expenses, vaccination costs, productivity losses due to missed workdays, and utility losses of COVID-19 patients in all age categories. To assess the cost-effectiveness of the program, we applied the Markov-SIR model, which has been validated and used in many studies related to COVID-19 prevention interventions.¹²⁻¹⁴ The evaluation was conducted from a societal perspective, assuming a discount rate of 3% annually for future costs and health effects. We constructed the model using TreeAge Pro 2020 and reported our analysis according to the Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement. The Markov-based SIR structure applied in this study does not allow for reinfection, which is a known limitation of classical SIR models. However, due to the short one-year horizon and national data indicating low reinfection rates during the Omicron wave in Iran, this assumption was considered acceptable. To address this uncertainty, the infection rate parameter was varied in one-way sensitivity analyses to indirectly account for the potential effect of reinfection. The 3% annual discount rate was selected based on standard recommendations from the World Health Organization (WHO) and the U.S. Panel on Cost-Effectiveness in Health and Medicine.^{15,16}

2.2. Model Structure

The model of COVID-19 infection and progression is illustrated in Figure 1, which depicts the various states that individuals can move into during each monthly cycle. These states include detected infection, undetected infection, non-infected, or death, and individuals can remain in their current state, as indicated by the arrows. Although the model is conceptually grounded in a Susceptible-Infectious-Recovered (SIR) framework, it was adapted to include clinical

disease progression states such as outpatient care, hospitalization, ICU admission, and death. These transitions reflect real-world treatment pathways and allow for health economic evaluation within a Markov structure.

Figure 1. Markov model of COVID-19 disease progression.



Patients in the detected infection state only remain there for one cycle, during which they enter a probability tree that allocates them through various levels of COVID-19 treatment, outpatient treatment, hospitalization, hospitalization + intensive care unit (ICU) admission, and hospitalization + ICU admission + mechanical ventilation to their final resolution of either recovery or death. Non-infected and recovered individuals remain in their states until they die of causes other than COVID-19 infection.

To assess the cost-effectiveness of vaccination compared to a non-vaccination scenario for each age group, we developed 2 hypothetical cohorts and followed them independently for their lifetime. The vaccination scenario includes partial vaccination, representing individuals who have received only 1 dose of the vaccine, and full vaccination, representing individuals who have received at least 2 doses of the vaccine. We assumed that individuals can only contract COVID-19 during the first year of the model and that the vaccine's effectiveness lasts up to 1 year. Additionally, we assumed that no reinfection occurs within the one-year period.

2.3. Model parameters

2.3.1. Transition probabilities

The model utilized COVID-19-related transition probabilities, which encompassed various stages of the disease. These probabilities included the monthly infection rate of symptomatic individuals, the likelihood of hospitalization for those infected, the probability of ICU admission for hospitalized patients, the possibility of mechanical ventilation for those admitted to the ICU, and the likelihood of death in all these categories. The data are shown in Table 1S.

Due to the lack of reliable age-specific data on symptomatic infection rates among unvaccinated individuals during the Omicron wave in Iran, we employed an indirect estimation method commonly used in epidemiological modeling, particularly during the COVID-19 pandemic. Specifically, we divided the observed age-specific hospitalization rates for unvaccinated individuals (obtained from the national COVID-19 registry) by the estimated hospitalization risk among symptomatic cases (derived from international studies). This back-calculation approach allowed us to estimate age-specific infection rates despite limited data. Similar methods have been applied in studies using U.S. CDC COVID-NET data and Health Affairs modeling^{17 18} We referred to previous studies to estimate the age-specific risks of hospitalization for COVID-19-infected patients during the Omicron era.¹⁹ Additionally, we estimated the COVID-19 symptomatic infection rates and risk of hospitalization for partially and fully vaccinated individuals by multiplying the vaccine efficacy by the infection rates and risk of hospitalization in non-vaccinated individuals, respectively.

We obtained data on the probability of ICU admission, mechanical ventilation, death, and length of stay in COVID-19 patients based on their age group and vaccination status. To do so, we analyzed data from 451262 hospitalized COVID-19 cases, which included 116001 nonvaccinated cases, 26302 partially vaccinated cases, and 303959 fully vaccinated cases.²⁰ The cases were sourced from the national system of the Medical Care Monitoring Center (MCMC) of the Iranian Ministry of Health and Medical Education (MOHME). We collected this data over 70 days, from January 21 to the end of March 2022, during the country's sixth hospitalization peak of COVID-19 in the Omicron (B.1.1.529)-dominant era. Patient information, such as name, age, sex, city of residence, clinical signs and symptoms, comorbidities, COVID-19 severity, ICU admission, ventilatory support (noninvasive and invasive), vaccination status, length of stay, and discharge status (death, complete or partial recovery, etc.), was recorded in the system. The data were collected from hospitals across the country. We calculated the point estimate and 95% confidence interval for each parameter based on age group and vaccination status (Table 1S).

The MCMC registry operates under standardized national protocols with regular data validation procedures, ensuring completeness and consistency across reporting units. These datasets are routinely used by the Iranian Ministry of Health for surveillance and policy decisions, supporting their credibility.

Also, the model did not explicitly account for underlying comorbidities such as diabetes or hypertension due to a lack of stratified data on comorbidity-specific outcomes in national registries during the study period. However, the increased severity associated with such conditions was indirectly reflected through higher age-specific hospitalization and mortality rates.

Although reinfection transitions were not explicitly modeled in the Markov-SIR structure, this uncertainty was addressed by varying the infection rate parameter across a wide, plausible range in the one-way sensitivity analyses. National data of Iran showed very low reinfection rates during the Omicron period, such as 0.03% in ICU patients.²¹ Global reports also indicated reinfection rates mostly under 10%, including 5.18% in Hong Kong,²² 9.72% in Mainland China,²³ and 1.8% in Malaysia,²⁴ while a meta-analysis estimated a global prevalence of 4.2%²⁵. Given these low rates and the one-year horizon, excluding reinfection transitions is unlikely to meaningfully affect ICER estimations. Moreover, sensitivity analyses confirmed that even under the highest infection rate scenarios, vaccination remained highly cost-effective.

2.3.2. Vaccine efficacy and supply

We obtained data on vaccination coverage from official websites that provide COVID-19 statistics, as well as from the Ministry of Health and Medical Education in Iran for 2021.²⁷ In our model, we assumed that the vaccination coverage rate was the same across all age categories. Vaccine efficacy was defined as the proportional reduction in COVID-19 infections, hospitalizations, and ICU admissions. The Sinopharm vaccine was the primary vaccine used in Iran, accounting for 80% of injections. We relied on the literature to determine its efficacy in preventing COVID-19 cases and hospitalizations during the Omicron (B.1.1.529) wave period.²⁸⁻³⁰ However, we were unable to obtain data on the efficacy of a single dose of the Sinopharm vaccine during our literature review; therefore, we used data on the efficacy of other vaccines belonging to the inactivated vaccine platform for partially vaccinated individuals in our model. According to the literature data on vaccine immunogenicity, we assumed that vaccine efficacy would not decrease over a one-year horizon (Table 2S).¹³

2.3.3. Costs

The cost of treating patients at different stages of infection was calculated by including the costs of outpatient visits and treatment, general hospitalization, ICU admission, ventilator support, and post-discharge costs for patients requiring ICU admission and mechanical ventilation. We derived these costs from health insurance data and hospitalized COVID-19 patient records. We obtained data on the cost of COVID-19 vaccination, including the unit price of COVID-19 vaccine per dose, wastage, and incremental system cost of introduction, from national official websites' reports regarding the COVID-19 vaccination program in Iran and the literature.^{31,32} Table 3S shows the mean duration of hospitalization only or ICU admission considering the use of a ventilator or not stratified by 3 subgroups of vaccination status (non-vaccinated, partially vaccinated, and fully vaccinated). The length of stay gradually increased every 10 years after 24 years, regardless of the vaccination status.

The cost of COVID-19 vaccines was treated as a fixed value based on average national procurement reports during the study period. To reflect uncertainty due to potential bulk purchase discounts or future price fluctuations, a plausible cost range was applied in the one-way sensitivity analysis.

The cost of the Sinopharm vaccine, which accounted for 80% of vaccine injections in Iran's vaccination program, was used as the index for calculations (Table 1).

Productivity losses were estimated by multiplying the average duration of COVID-19 symptoms, including duration for outpatients and length of stay in the hospital, by workforce participation rates and average daily wages. We extracted workforce participation rates for different age groups and average daily wages from the National Statistics Center of Iran websites and entered them into the model (Table 1).³³ All the costs were converted to US dollars (USD) by using the average exchange rate in 2021 (1USD = 262931 IR Rials).

Table 1. COVID-19 vaccination cost, COVID-19 related hospitalization cost, costs for hospitalized patient requiring ICU + ventilator

Variable		Mean	Lower limit	Upper limit
COVID-19 vaccination cost (\$ US)	Unit price of COVID-19 vaccine (per dose)	9.20	6.00	10.00
	Wastage (\$ US)	0.46	0.30	0.50
	Incremental system costs of introduction (\$ US)	1.13	1.02	1.24
	Total cost of vaccination per dose (\$ US)	10.79	7.32	11.74
Outpatient treatment cost (\$ US)		19.02	15.21	22.82
COVID-19 related Hospitalization cost (\$ US)	Hospitalized patient not requiring ICU or ventilator	286.66	267.65	305.68
	Hospitalized patient requiring ICU	650.39	630.98	668.83
	Hospitalized patient requiring ICU + ventilator	797.14	685.55	908.73
After discharged costs for hospitalized patient requiring ICU + ventilator (\$ US)		94.82	79.61	117.64
Daily wage (\$ US)		9.51	7.61	13.31
Workforce participation rate (%)	18-24 years	59.10	55.00	65.00
	25-34 years	53.00	50.00	56.00
	>=35 years	46.50	43.00	49.00

2.3.4. Health Utilities

We obtained utility weights for the normal population in all age categories in Iran by referring to previous national studies on the quality of life in Iran.³⁴ We also obtained utility losses for various disease progression states, including symptomatic infection, general hospitalization, and ICU admission with and without mechanical ventilation, from the literature. These utility weights and losses were used in our model to estimate the overall health impact of COVID-19 vaccination (Table 2). Utility weights for different health states were obtained from previously published COVID-19 cost-utility studies and are summarized along with their sources in Supplementary Table 1S.

Table 2. Utility weights for different health states

Variable		Mean	Lower limit of 95% CI	Upper limit of 95% CI
Utility weights for the normal population	18-34 years	0.87	0.83	0.91
	35-44 years	0.83	0.79	0.87
	45-54 years	0.78	0.74	0.82
	55-64 years	0.75	0.71	0.79
	65-75 years	0.74	0.70	0.78
	>75 years	0.67	0.64	0.70
Detected infection symptoms disutility weight		0.19	0.171	0.209
Detected infection hospitalization as the highest setting disutility weight		0.30	0.27	0.33
Detected infection hospitalization with ICU as the highest setting disutility weight		0.50	0.45	0.55
Detected infection hospitalization with ICU + ventilator as the highest setting disutility weight		0.60	0.54	0.66

Note: All utility values are presented on a scale from 0 (equivalent to death) to 1 (full health). Disutility values ranged from 0 (representing no disutility or the state is neutral or desired) and 1, representing maximum disutility.

2.4. Base case analysis

Using these utility weights and losses, we were able to estimate the overall health impact of COVID-19 vaccination in our model. Specifically, we calculated the number of COVID-19 symptomatic cases, hospitalizations, ICU admissions, and deaths averted over one year, as well as the corresponding direct healthcare and productivity costs saved and QALYs gained. Our analysis was conducted from a societal perspective. Furthermore, we determined the incremental costs and incremental QALYs for the vaccination strategy compared with no vaccination. To assess the cost-effectiveness of the vaccination strategy, we calculated the incremental cost-effectiveness ratio (ICER), which represents the incremental cost per QALY gained. Our willingness-to-pay (WTP) threshold for ICER was set to < USD 4091. The selection of input parameters, summarized in Supplementary Table 1S, was based on a combination of data sources. Whenever available, we used real-world national data from the Medical Care Monitoring Center (MCMC) and the Ministry of Health and Medical Education (MOHME). For parameters lacking local data, values were extracted from published literature, prioritizing studies conducted in Middle Eastern or LMIC settings. In cases where neither local data nor reliable literature was available, parameter estimates were informed by expert consensus from national epidemiologists and health economists. All sources are documented in the supplementary materials.

Vaccine efficacy was assumed to remain constant throughout the one-year modeling period. While this assumption does not account for potential waning immunity, a wide range of efficacy values was tested in one-way sensitivity analyses to capture this uncertainty.

2.5. Sensitivity analysis

In one-way sensitivity analysis, one input (such as vaccine efficacy or cost) is varied at a time, while all other parameters are held constant. This approach identifies which inputs have the greatest influence on the model outcomes, particularly the Incremental Cost-Effectiveness Ratio (ICER). To address uncertainty in the model, one-way sensitivity analyses were performed by varying each parameter individually across a predefined plausible range obtained from published literature or expert input. The 10 most influential parameters were identified based on how variations in their values affected the ICER. These parameters were visually represented in a tornado diagram. Due to the lack of reliable distributional data for several key inputs and the limited one-year time horizon, probabilistic sensitivity analysis (PSA) using Monte Carlo simulation was not conducted. This limitation has been acknowledged, and PSA is recommended for future models with richer datasets and extended

projection periods. Given the one-year time horizon of the present study, the impact of discounting on the results was minimal; therefore, assigning a distribution to the discount rate in sensitivity analyses was not deemed necessary.

Although not performed in this study, future analyses could benefit from incorporating probabilistic sensitivity analysis (PSA) using Monte Carlo simulation to better capture the joint uncertainty across multiple model parameters, particularly in longer-term projections or more complex policy evaluations. Additionally, reinfection rates and variant-specific severity were not modeled explicitly due to data limitations, their potential effects were indirectly addressed by varying key parameters such as infection rate, hospitalization risk, and case fatality in the one-way sensitivity analyses.

3. Results

3.1. Primary results

Over a one-year period, 60655600 people were at risk of COVID-19. No vaccination resulted in 20317221 new cases, 1510803 hospitalizations, and 135115 deaths from COVID-19. However, the vaccination program prevented 2078176 infections, 833951 hospitalizations, 87273 ICU admissions, and 43161 deaths in all age groups (Table 3). The average cost per individual for the vaccination program was \$39.68, while the non-vaccination cost was \$25.6 per person. Compared to the nonvaccinating scenario, vaccination resulted in an average of \$14.08 more cost per person and produced an average of 0.035 additional QALYs per person. Although vaccination was not cost-saving compared to nonvaccinating, it was still considered a cost-effective strategy due to generating an average of 0.035 incremental QALYs per person. Overall, vaccination generated an extra 2098495 QALYs at a total extra cost of \$853.78 million. The average incremental cost per QALY saved in the vaccination scenario was \$406.85 in the adult population. This value corresponds to the vaccinated population, not the entire national population. For better interpretability, this equates to approximately 3500 QALYs per 100,000 vaccinated individuals. Based on one-way sensitivity analysis, these three parameters, vaccine cost per dose, hospitalization risk in unvaccinated individuals, and vaccination coverage among individuals aged 18–64, produced the largest variations in ICER values across all age-specific models. These results were derived from the tornado diagram, which ranked parameters by their influence on the outcome.

Age Group	Above 64 years		55-64 years		45-54 years		35-44 years		25-34 years		18-24 years		All Age	
	No n- Va cci na te d	Va cci na te d	No n- Va cci na te d	Va cci na te d	No n- Va cci na te d	Va cci na te d	No n- Va cci na te d	Va cci na te d	No n- Va cci na te d	Va cci na te d	No n- Va cci na te d	Va cci na te d	No n- Va cci na te d	Va cci na te d
Vaccination status														
Population at risk	5,691,000	5,691,000	6,968,000	6,968,000	10,192,000	10,192,000	15,548,000	15,548,000	14,541,000	14,541,000	7,715,600	7,715,600	60,655,600	60,655,600
COVID-19 infections	1,938,678	1,740,596	3,188,986	2,889,377	3,621,753	3,254,072	4,756,744	4,258,029	4,449,854	3,983,320	2,361,207	2,113,652	20,317,221	18,239,046
Hospitalizations	350,901	157,213	207,284	93,719	235,414	105,548	294,918	131,738	275,891	123,239	146,395	65,394	1,510,803	676,851
ICU Admissions	67,022	25,970	23,216	8,370	17,656	17,6520	12,976	3,904	8,829	2,584	5,417	1,495	135,115	47,843
COVID-19 Deaths	41,194	14,289	9,684	3,074	6,947	1,907	4,106	1,062	1,324	414	845	196	64,101	20,940
Decreased infections		198,082		299,609		367,681		498,715		466,534		247,555		2,078,176
Decreased		193,		113,		129,866		163,180		152,652		81,001		833,951

hospitalizations		688		565										
Decreased ICUs		41,052		14,846		12,136		9,073		6,244		3,922		87,273
Decreased Deaths		26,905		6,610		5,041		3,045		911		649		43,161
Average Cost (\$ US)	40.41	45.86	33.00	45.64	25.20	39.67	21.11	36.73	22.37	37.90	23.71	39.05	25.60	39.68
Incremental Cost (\$ US)		5.45		12.64		14.47		15.62		15.54		15.34		14.08
Average QALY	4.32	4.37	8.18	8.21	10.99	11.03	12.89	12.92	14.43	14.46	15.43	15.47	11.92	11.95
Incremental QALY		0.047		0.033		0.034		0.034		0.034		0.034		0.035
Incremental cost effectiveness ratio(\$ US)		114.92		380.57		429.17		469.51		471.17		461.22		406.85

Table 3. Calculation of average cost, incremental cost, average QALY, incremental QALY, and incremental cost-effectiveness ratio of COVID-19 vaccines in Iran in different age groups of non-vaccinated and vaccinated COVID-19 patients

3.2. Base case results

3.2.1. Incremental benefits of vaccination in the age group of 18-24 years

In the age group of 18-24 years, vaccination prevented a total of 247555 infections (11.9% of the total adult population prevented), 81001 hospitalizations, 3,922 ICU admissions, and 649 deaths over one year. However, this group had the lowest hospitalizations averted (9.71% of the total prevented hospitalizations), ICU admissions averted (4.49% of the total adult population prevented ICU admissions), and death cases averted (1.5% of the total population's prevented deaths) compared to other age groups.

The incremental cost for vaccinating individuals over 64 years was the lowest at \$5.45, while those under 64 years had an incremental cost ranging between \$12.64 and \$15.54. The average incremental cost for this age group was \$15.34, with an average gain of 0.033 QALYs per person. The total ICER for this group was \$461, which was higher than the average ICER for all adult populations.

An average \$15.34 incremental cost was incurred by vaccinating this age group, and an average of 0.033 QALY was gained per person. The total ICER was \$461 for this group, which was higher than the average ICER for the adult population.

3.2.2. Incremental benefits of vaccination in the age group of 25-34 years

Compared to other age groups, the vaccination program yielded the lowest cost-effectiveness in the 25-34 age group, with an ICER of \$471 per QALY generated. This age group accounted for 22.44% of the total prevented infections (466534 cases), 18.30% of prevented hospitalizations (152652 cases), 7.15% of prevented ICU admissions (6244 cases), and 2.11% of prevented deaths (911 cases) due to vaccination.

3.2.3. Incremental benefits of vaccination in the age group of 35-64 years


The age group with the most infections averted was 35-44 years old, with 498715 cases averted. In contrast, the age group over 64 years only accounted for 9.53% of the total averted new infections in the adult population. Table 3 provides detailed information on the incremental benefits of vaccination for people aged 45 to 64 years old.

3.2.4. Incremental benefits of vaccination in the age group of over 64 years

Vaccination prevented a total of 198082 new infections, 193688 hospitalizations, 41052 ICU admissions, and 26905 deaths in individuals over the age of 64 years. The ICER was lowest for this age group and increased with each decade below 64 years until reaching a peak at 25-34 years old. Among all age groups, vaccination was most cost-effective and effective in individuals over 64 years old. This age group gained the most incremental QALYs and accounted for the highest number of prevented hospitalizations (193688) with the least

incremental cost (\$5.45). However, vaccination had the least impact on preventing infections in individuals over 64 years old, with only 198082 cases averted. This age group also had the most prevented ICU admissions (41052) and deaths due to vaccination. Overall, vaccination was more cost-effective in individuals over 64 years old compared to other age groups. Figure 2 demonstrates the incremental benefits of decreased COVID-19 infection cases and severe clinical outcomes of the COVID-19 vaccination strategy in various age groups.

Figure 2. The incremental benefits of decreased COVID-19 infections cases and severe clinical outcomes of the COVID-19 vaccination strategy in varied age groups in Iran



The




figure shows a comprehensive overview of the incremental benefits of vaccination across age groups, including reductions in infection, hospitalization, ICU admissions, and deaths. The aim was to provide a how outcomes vary by age.

3.3. Sensitivity analyses


The cost of the COVID-19 vaccine per dose, risk of hospitalization in nonvaccinated patients, and coverage of vaccination in individuals aged 18-64 years were the most sensitive parameters in all age-based sensitivity analyses. For those over 64 years old, the most sensitive parameters were the cost of COVID-19 vaccine per dose, COVID-19 symptomatic infection rate, and risk of hospitalization in nonvaccinated COVID-19 patients.

The cost of vaccine per dose was the most influential parameter affecting ICER, with an increase in cost leading to an increase in ICER. The ICER varied widely when vaccine cost changed within a range of \$7.32 to \$11.74 per injection. Vaccination was even cost-saving for those over 64 years old when the vaccine price was at its lowest value. The highest ICER value was observed in those aged 25 to 35 years, with a vaccination cost of \$525.

A higher risk of hospitalization in non-vaccinated COVID-19 patients and increased vaccination coverage decreased the ICER. For those over 64 years old, higher symptomatic COVID-19 infection rates decreased the ICER. All results were robust in sensitivity analysis, with vaccination remaining cost-effective even after changing parameter ranges. The Tornado diagrams are available in Figures 3A to 3F.

Figure 3– Sensitivity analysis: Tornado diagram A to F according to different age groups. Tornado diagram showing the impact of the sensitivity analyses on the incremental cost per quality-adjusted life-year gained of vaccination compared to no vaccination. A horizontal bar was generated for each parameter analysis. The width of the bar indicates the potential effect of the associated parameter on the ICER when the parameter is changed within its range. The red part of each bar indicates high values of input parameter ranges, while the blue part indicates low values.


A) Tornado diagram age 18-24 year:



Variable Description	Variable Value		ICER	
	Lowest	Highest	Lowest	Highest
Cost of covid vaccine per dose(\$ US)	7.32	11.74	263.00	515.49
Risk of hospitalization in Covid-Non vaccinated patients	0.04	0.07	446.24	503.21
coverage of vaccination	0.75	0.85	435.42	488.90
COVID-19 Symptomatic infection rate (monthly)	0.02	0.04	436.92	489.49
vaccine efficacy in reducing the incidence of symptomatic COVID-19	0.095	0.228	437.26	486.63
Duration of COVID-19 symptoms for outpatients(days)	5	10	444.29	472.54
Average Daily wage	7.61	13.31	442.94	470.36


Hospitalization cost for patient not requiring ICU or ventilator	267.65	305.68	455.51	466.93
Percent of fully vaccinated from all vaccinated population	0.88	0.92	455.97	466.47
Fully Vaccination efficacy in reducing Hospitalization of symptomatic COVID-19 patients (%)	0.614	0.701	456.90	466.07

B) Tornado diagram age 25-34 year:



Variable Description	Variable Value		ICER	
	Lowest	Highest	Lowest	Highest
Cost of COVID-19 vaccine per dose	7.32	11.74	271.23	525.91
Risk of hospitalization in COVID-19 non-vaccinated patients	0.04	0.07	456.95	510.80
coverage of vaccination	0.75	0.85	445.48	498.71
Vaccine efficacy in reducing the incidence of symptomatic COVID-19	0.095	0.228	448.43	495.30
COVID-19 Symptomatic infection rate (monthly)	0.02	0.04	450.25	495.53
Duration of COVID-19 symptoms for outpatients (days)	5	10	455.76	481.47
Average Daily Wage	7.61	13.31	454.67	479.42
Hospitalization cost for patient not requiring ICU or ventilator (US\$)	267.65	305.68	465.36	476.97
Percent of fully vaccinated from all vaccinated population	0.88	0.92	465.83	476.51
Fully Vaccination efficacy in reducing Hospitalization of symptomatic COVID-19 patients (%)	0.614	0.701	466.71	476.17


C) Tornado diagram age 35-44 years:



Variable Description	Variable Value		ICER	
	Lowest	Highest	Lowest	Highest
Cost of Covid-19 vaccine per dose	7.32	11.74	271.35	523.76
Risk of hospitalization in Covid-19 non-vaccinated patients	0.04	0.07	452.48	518.07
COVID-19 Symptomatic infection rate (monthly)	0.02	0.04	443.65	499.63
coverage of vaccination	0.75	0.85	443.63	497.31
Fully Vaccination efficacy in reducing the incidence of symptomatic COVID-19	0.095	0.228	448.49	491.82


Duration of COVID-19 symptoms for outpatients (days)	5	10	456.03	478.52
Average Daily wage	7.61	13.31	455.00	476.76
Hospitalization cost for patient not requiring ICU or ventilator	267.65	305.68	463.84	475.17
Percent of fully vaccinated from all vaccinated population	0.88	0.92	464.14	474.87
Fully Vaccination efficacy in reducing Hospitalization of symptomatic COVID-19 patients (%)	0.614	0.701	465.03	474.54

D) Tornado diagram age 45-54 year:



Variable Description	Variable Value		ICER	
	Lowest	Highest	Lowest	Highest
Cost of the COVID-19 vaccine per dose	7.32	11.74	233.69	482.68
coverage of vaccination	0.75	0.85	399.67	461.36
Risk of hospitalization in COVID-19 non-vaccinated patients	0.05	0.07	414.56	475.17
Fully vaccinated efficacy in reducing the incidence of symptomatic COVID-19	0.095	0.228	405.51	454.21
COVID-19 Symptomatic infection rate (monthly)	0.03	0.04	415.90	450.79
Average Daily Wage	7.61	13.31	412.55	437.48
Duration of COVID-19 symptoms for outpatients(day)	5	10	414.28	439.12
Hospitalization cost for a patient not requiring ICU or ventilator	267.65	305.68	422.65	435.68
Fully Vaccination efficacy in reducing Hospitalization of symptomatic COVID-19 patients (%)	0.614	0.701	423.46	435.59
Percent of fully vaccinated from all vaccinated population	0.88	0.92	424.35	433.97


E) Tornado diagram age 55-64 year:



Variable Description	Variable Value		ICER	
	Lowest	Highest	Lowest	Highest
cost of Covid-19 vaccine per dose (\$ US)	7.32	11.74	182.07	434.92
Risk of hospitalization in COVID-19 non-vaccinated patients	0.05	0.07	361.13	443.11
coverage of vaccination	0.75	0.85	344.90	420.55

Fully vaccinated efficacy in reducing the incidence of symptomatic COVID-19	0.095	0.228	351.35	411.30
COVID-19 Symptomatic infection rate (monthly)	0.04	0.06	354.33	411.79
Average Daily Wage	7.61	13.31	359.74	390.99
Duration of COVID-19 symptoms for outpatients (days)	5	10	362.66	392.55
Fully Vaccination efficacy in reducing Hospitalization of symptomatic COVID-19 patients (%)	0.614	0.701	372.01	390.25
Hospitalization cost for a patient not requiring ICU or ventilator	267.65	305.68	372.46	388.68
Risk of ICU admission + ventilator in hospitalized non-vaccinated patient	0.032	0.038	375.31	385.94

F) Tornado diagram age >64 year:



Variable Description	Variable Value		ICER	
	Lowest	Highest	Lowest	Highest
Cost of COVID-19 vaccine per dose	7.32	11.74	(24.09)	152.98
COVID-19 Symptomatic infection rate (monthly)	0.02	0.04	79.12	250.38
Risk of hospitalization in COVID-19 non-vaccinated patients	0.15	0.2	82.00	175.06
Coverage of vaccination	0.75	0.85	90.31	141.91
Fully vaccinated efficacy in reducing the incidence of symptomatic COVID-19	0.095	0.228	94.47	136.83
Fully Vaccination efficacy in reducing Hospitalization of symptomatic COVID-19 patients (%)	0.614	0.701	102.57	129.03
Average Daily Wage	7.61	13.31	97.76	123.51
Hospitalization cost for a patient not requiring ICU or ventilator	267.65	305.68	104.17	125.67
Duration of COVID-19 symptoms for outpatients (days)	5	10	105.07	121.51
Hospitalization cost of a COVID-19 patient requiring ICU + ventilator	685.55	908.73	108.90	120.95

4. Discussion

In this study, we assessed the cost-effectiveness of the COVID-19 mass vaccination program during the Omicron era in Iran. Our results indicated that the vaccination strategy significantly reduced the incidence of infections, hospitalizations, ICU admissions, and deaths among adults in all age groups when compared to no vaccination. The vaccination program averted a total of 2078176 infections, 833951 hospitalizations, 87273 ICU admissions, and 43161 deaths across all age groups. The number of deaths prevented ranged from 649 deaths in the 18-24 age group to 26905 deaths in those over 64 years.

The cost-effectiveness threshold is the maximum amount that decision-makers are willing to pay for a unit of health outcome based on the country's gross domestic product per capita.³⁵ The 25 ICER threshold for cost-effectiveness was 4091 (1time GDP per capita) per QALY. The average incremental cost per QALY saved in the vaccination scenario was 406.85 per QALY in adult people regardless of their age group, which is about 0.16 times the cost-effectiveness threshold in Iran.

The vaccination strategy resulted in a gain of 2098495 QALYs during a one-year period. The ICER was lowest for those over 64 years old and increased by every 10 years below 64 years old until 25 years old. Vaccination was found to be a highly cost-effective intervention in all population groups. Additionally, our results were robust in an extensive sensitivity analysis. These findings are consistent with evidence from other countries that found vaccination to decrease COVID-19 infection and death compared to a no-vaccination strategy and increase clinical benefits.^{10,36-39} However, an important difference between our study and others is that our cost-effectiveness analyses were based on real data after a mass vaccination program rather than prospective simulations before vaccination.

Vaccination in patients over 64 years brought the most cost-effectiveness among all age groups of the population, accounting for the higher proportion of decreased infections, hospitalizations, ICU admissions, and deaths, and accordingly, a lower value of ICER, as we found the ICER was the lowest for the elderly age group. Therefore, vaccinating this population is likely to be considered a great priority.¹³ Several studies have agreed that prioritizing vaccination for the elderly population brings more effectiveness and could be even cost-saving compared to the all-age vaccination strategy. A study conducted by Orangi S et al. in Kenya showed because of the low proportion of the elderly population in Kenya (11% of the total population is aged 50 years and above), prioritizing them in the vaccination strategy was highly cost-effective, even with low vaccine coverage (only 30% coverage), while the expansion of vaccination to whole population needed great vaccine coverage to achieve cost-effectiveness.⁴⁰

Elderly people are at higher risk of contracting severe forms of infection and have a higher chance of increasing comorbidities leading to severe infection complications, hospitalization, ICU admissions, and deaths.¹³ Moreover, the highest values of direct health costs belonged to the patients who were admitted to the ICU and needed mechanical ventilation. Thus, preventing infection and severe disease in the elderly would bring a high cost-effectiveness as they account for the highest proportion of hospitalizations and deaths among all age groups of the population. A study conducted by Li R et al. extensively evaluated the cost-effectiveness of a BNT162b2 booster strategy among older adults aged ≥ 65 years in the United States and demonstrated that with every dollar of investment in the booster vaccination, the US government might save nearly \$2 because of fewer COVID-19 hospitalizations. Notably, the cost-effectiveness of the booster strategy is highly sensitive to the incidence of COVID-19, consistent with our results, which showed that the more the risk of death and hospitalization increased, the more cost-effective the vaccination program.¹⁴

Studies conducted in the UK, the US, and Madagascar have accordingly shown that prioritizing older ages and taking the proportion of the older population into account based on population demographics could bring better cost-effectiveness in different regions.^{36,38-40} In contrast to previous studies highlighting the cost-effectiveness of prioritizing vaccination for the elderly population, Pearson et al. conducted a study in Pakistan that found unprioritized vaccination would bring greater benefits. This is attributed to the demographic context of LMICs, which have a younger population and higher previous infection rates compared to high-income countries.^{10,41} Additionally, vaccines that only protect against the disease rather than infection transmission have even lower benefits in these settings. Similar results were observed in a study in South Africa, indicating that achieving cost-effectiveness when targeting the entire population will require high coverage of vaccination in settings with a lower proportion of elderly individuals and a higher probability of previous exposure to COVID-19.^{10,37,40} The young population is actively working and has high-transmission tendencies; therefore, vaccinating them with even less effective vaccines but a high coverage would decrease the transmission of infection in the whole population and decrease the probability of infection in older ages, indirectly protecting this vulnerable group.^{10,42} A better cost-effectiveness profile would have been achieved when taking productivity losses into account from a societal perspective rather than a health system's perspective, which considers only direct health system costs; As observed in the studies of Turkey and Pakistan, taking into account productivity losses even made the vaccination program cost-saving rather than just cost-effective, while the productivity losses were not considered.^{10,40,43} These findings mirror the

results of our study. The young population has accounted for a high proportion of the population in Iran. At the same time, a greater proportion of infections averted with vaccination belongs to the population aged 18-45 years, accounting for 73% of total infections averted in the adult population through vaccination. Although we found the incremental cost per QALY generated was highest in ages 18-45 years, and they developed a lower proportion of averted hospitalizations, ICU admissions, and deaths after vaccination compared to the elderly population, vaccinating this population with a high coverage still brought a high beneficial value as the ICER was still far from reaching the cost-effectiveness threshold. The reason is that the young population has a potentially lower overall risk of developing severe infection leading to hospitalization and death and is more likely to get mild and or asymptomatic COVID-19 infection. Moreover, they have a higher chance of being previously exposed to the infection and developing natural immunity. Nevertheless, as they are active working groups with higher value of productivity, preventing them from being infected not only decreases the costs indirectly incurred on the economy but also indirectly protects the vulnerable population by averting severe infections leading to hospitalization and death.

Based on our findings, vaccination was not cost-saving compared to the non-vaccination scenario in any age group. It could have several reasons. In many studies, the effectiveness of the vaccines was considered in the period of early strains of the virus, but in this study, the effectiveness of the vaccine was based on the extracted real data in the Omicron period with lower effectiveness because of decreased pathogenicity, rate of hospitalization, and death. Furthermore, we did not estimate the direct influence of infection transmission reductions by vaccination among the population individuals, and the real beneficial effect could be greater than what we roughly calculated.¹³ Besides, in Iran, the costs of hospitalization and treatment are much lower than in Western countries due to lower wage rates and the existence of hidden subsidies in the economy, while the price of vaccines is similar to other countries. Thus, the vaccination program and reducing the cost of treatment in other countries lead to much more profit compared to Iran. While comparable cost-effectiveness studies in other low- and middle-income countries (LMICs) often support prioritization of elderly populations due to higher mortality risk¹, Iran's relatively younger demographic structure poses different policy considerations². Our model demonstrated that vaccination among adults aged 18–64 years was highly cost-effective, largely due to their higher representation in the workforce and their role in transmission. Therefore, age-based prioritization strategies should be context-specific, taking into account both clinical risk and demographic realities⁴⁴ This study relied on a combination of real-world data for the vaccination scenario and modeled assumptions for the

counterfactual non-vaccination scenario. While this approach allows for practical relevance, it introduces inherent uncertainty in comparative outcomes. Moreover, unlike some LMIC-based studies that have reported COVID-19 vaccination to be cost-saving, our findings indicated cost-effectiveness but not universal cost-saving. This discrepancy may be attributed to Iran's lower healthcare costs, younger population structure, and limited treatment expenditures relative to other countries. These differences highlight the importance of contextualizing economic evaluations within national health and cost frameworks.

In this study, we only calculated the benefits of preventing productivity loss without considering suppression policies. These policies enforced by the governments had substantial net benefits in terms of preventing losses to economic output; on the other hand, suppression policies resulted in substantial losses to the GDP, too. In total, the net benefits of suppression policies on total economic production were positive and likely substantial. In contrast, Jiang Y et al. analyzed the cost-effectiveness of vaccinating 50% of the population in Hong Kong SAR (special administrative regions), Indonesia, mainland China, Philippines, Singapore, and Thailand, suggesting that the vaccination strategy was not only cost-effective but also created sizeable net monetary benefit (NMB). Whereas the deterministic results were robust to parameter variations, the magnitude of NMB increased with the incidence of COVID-19 and the population coverage of vaccines.⁴⁵

According to the WHO, interventions that cost less than 3times GDP per capita are cost-effective, while those that cost less than 1times GDP per capita are highly cost-effective.⁴¹ Based on this, vaccination was highly cost-effective in all age groups of the adult population in this study. None of the imputed parameters could change the conclusion that vaccination was a cost-effective intervention in the adult population at risk of COVID-19. The highest value of ICER extracted from the different ranges of imputed parameters in the sensitivity analysis was far below the willingness to pay threshold, which was equal to 1 GDP per capita in our study. Changing the model parameters' values in their range did not alter the conclusion on the cost-effectiveness of vaccination strategies, and consistent results with the base analyses were obtained from sensitivity analyses. The robust result of the sensitivity analyses brings certainty about model inputs.⁴¹ Results of the sensitivity analyses showed that the price of the vaccine per dose was the most influential parameter to determine the value of the incremental cost-effectiveness of vaccination. The ICER value varied widely when the price of the vaccine changed in its range, making this parameter the most sensitive factor to determine the cost-effectiveness of the vaccination program. Vaccination with low-priced vaccines was even cost-saving in over 64 years, according to our analysis. Consistent with our result, in a

systematic review of studies on the cost-effectiveness of COVID-19 vaccines in multiple countries, one of the most important parameters in determining the cost-effectiveness of the vaccination program was vaccine cost.⁴⁶ In the sensitivity analyses of 12 large LMICs, the vaccination program cost was the most influential factor in determining cost-effectiveness.⁴⁷ Although vaccination has been a cost-effective or cost-saving strategy in both high and low- and middle-income countries, due to the limited resources, the affordability of vaccines is an important aspect of the mass vaccination program, and the same vaccines and doses cannot be supplied in all countries.^{10,41,46} For low per-dose vaccine prices, either prioritized or non-prioritized strategies would be cost-effective, while high-price vaccines may not be cost-effective depending on their characteristics, vaccination strategy, and pandemic trends.¹⁰ Other influential parameters were the risk of hospitalization in non-vaccinated COVID-19 patients, vaccination coverage, and vaccine efficacy in reducing symptomatic infection. We concluded that vaccine prices, hospitalization costs, and vaccine efficacy were the important parameters evaluated in sensitivity analyses of different studies.

This study has several strengths. First, it was a national study that utilized a combination of real data and modeling rather than relying solely on assumptions. The study included all adult age groups and assessed the effects of different vaccine platforms, including fully and partially vaccinated individuals, as well as those with no vaccine status. The study also evaluated several outcomes, such as the length of hospital or ICU stay and mortality.

However, it is important to interpret these findings within the context of certain limitations. The SIR-Markov model used in this study cannot predict future epidemics or new variants of COVID-19. Therefore, it is important to consider all available resources when interpreting these findings for public health initiatives related to vaccination and epidemic management. The study did not take into account important underlying diseases, such as diabetes and hypertension, nor did it examine different vaccine platforms. Additionally, we assumed that no reinfection occurs within the one year. We acknowledge that this assumption may oversimplify COVID-19 dynamics, particularly with emerging variants that could influence reinfection rates. Reinfection was considered a secondary factor, as initial vaccine effectiveness is generally high and immunity decay in the first year is gradual. Incorporating reinfection would add complexity, but its impact on the model's conclusions would be limited within the one-year timeframe. Notably, national studies' evidence has indicated a low recurrent infection rate in Iran during one year.²⁰ We assumed that vaccine efficacy would not decrease over a one-year horizon. While this assumption may slightly affect the incremental cost-effectiveness ratio (ICER), the impact is expected to be unremarkable, as our primary focus was on short-term

health outcomes and economic benefits. Extending the model timeframe or projecting further could require incorporating waning immunity more comprehensively, particularly in light of booster requirements and emerging variants. The study did not assess the long-term complications of COVID-19 and social outcomes of the COVID-19 pandemic, which could further increase the economic burden of the disease when not vaccinating, as well as the limitation of critical care capacity during the peak of the Omicron COVID-19 outbreak. On the other hand, COVID-19 vaccine complications could be simultaneously considered. Finally, the study did not consider patient overcrowding or critical care capacity during the peak of the Omicron COVID-19 outbreak, which may underscore the importance of mass vaccination, especially in low- and middle-income countries with large populations. Given the one-year time horizon and national surveillance data indicating low reinfection rates during the Omicron wave in Iran, transitions from recovered to susceptible were excluded. While this may underestimate the true transmission dynamics, one-way sensitivity analyses incorporating a wide range of infection rates were conducted to account for the potential effects of reinfection. Therefore, this limitation is unlikely to significantly affect the overall conclusions of the model.

Another methodological limitation is the application of a 3% discount rate, which, although consistent with international guidelines, may not reflect Iran's economic environment. Given the one-year model horizon, this had a limited impact, but future evaluations with longer timeframes should consider locally appropriate rates. The model did not incorporate waning vaccine immunity over time, which may overestimate long-term protection. However, sensitivity analyses involving a range of efficacy values partially addressed this limitation. More dynamic modeling approaches are recommended for studies with longer time horizons or booster dose evaluations. Another limitation is that vaccine effectiveness was modeled as a single averaged value without differentiating between vaccine types. Although Sinopharm accounted for the majority of doses administered, this approach may not capture potential variability in protection across different vaccine brands. The findings of this study are based on epidemiological and healthcare data from Iran during the Omicron wave and may not be generalizable to other variants with different transmission dynamics or to countries with different healthcare infrastructures and vaccine coverage. Caution should be taken when extrapolating these results to other settings without appropriate model recalibration. Also, the model did not incorporate critical care capacity constraints during COVID-19 surges, such as ICU bed shortages. This simplification may underestimate the full benefits of vaccination in preventing hospital overload, treatment delays, and excess mortality caused by strained healthcare resources.

While the analysis incorporated key healthcare and individual-level societal costs, it did not extend to capturing broader macroeconomic consequences of the pandemic, such as national GDP fluctuations, lockdown-induced business closures, or large-scale economic slowdowns. As a result, the estimated economic benefit of vaccination may represent a conservative approximation of its total value to society. Although this analysis focused on economic outcomes, equity and feasibility issues remain important. The model did not assess disparities in vaccine access or challenges in achieving high coverage in resource-limited settings. Real-world constraints such as logistical barriers and vaccine hesitancy may limit the impact of vaccination programs and should be considered in policy planning. The exclusion of reinfection may lead to a slight underestimation of the total disease burden; however, given the low observed reinfection rates during the study period, its impact on the economic outcomes and overall cost-effectiveness conclusions is likely negligible.

5. Conclusion

In summary, cost-effectiveness analysis plays a fundamental role in decision-making and the implementation, evaluation, and monitoring of public policies. Our epidemiological approach for assessing the impact of vaccination strategies against COVID-19 constitutes a tool that articulates scientific knowledge, empirical evidence, and public policies in a framework for interaction with users, analysts, and decision-makers. Expanding the vaccination strategy to eligible individuals would be cost-effective, as it would result in a significant gain of QALYs by increasing some extra costs. Therefore, the COVID-19 vaccination program was health-beneficial and highly cost-effective in Iran.

Data availability statement

The data that support the findings of this study are available from the corresponding author upon request.

Ethical consideration, consent and permissions

National Committee for Ethics in Biomedical Research of Iran had declared a prior mandate that all COVID19 patients admitted to any medical facility must be made fully aware of their potential participation to research projects. All patients were requested to sign an informed consent form which contained the permission to transfer their electronic data, confidentially, to the HIS (hospital information system) which are connected to the national registry of the

Medical Care Monitoring Center (MCMC) of the Iranian Ministry of Health for data collection and publication, future investigations, and research.

This study was approved by the Iran National Committee for Ethics in Biomedical Research (Ethic code: IR.SBMU.NRITLD.REC.1402.088) and followed the ethical guidelines of the Declaration of Helsinki.

Acknowledgments

The authors would like to express their gratefulness to the staff and researchers of the Iran Ministry of Health and Medical Education.

Author contributions

Dr. Shafaghi had full access to all of the data in the study and takes full responsibility for the integrity of the data and the accuracy of the data analysis.

Substantial contributions to the conception or design of the study

Hamidreza Jamaati, Maryam Hajimoradi, Fariba Ghorbani, Rajabali Daroudi, Shadi Shafaghi, Fatemeh Sadat Hosseini-Baharanchi, Saeed Karimi, Yunes Panahi, Ali Akbari Sari, Seyed Mohsen Zahraei, Shahnam Arshi, Fatemeh Nouri

Data acquisition and analysis

Fatemeh Sadat Hosseini-Baharanchi, Maryam Hajimoradi, Hamidreza Jamaati, Fariba Ghorbani, Shadi Shafaghi, Rajabali Daroudi, Mahshad Goharimehr, Shahnam Arshi, Fatemeh Nouri

Study data Interpretation

Rajabali Daroudi, Mahshad Goharimehr, Hamidreza Jamaati, Fatemeh Sadat Hosseini-Baharanchi, Maryam Hajimoradi, Fariba Ghorbani, Shadi Shafaghi, Ali Akbari Sari, Seyed Mohsen Zahraei, Farzaneh Dastan

Drafting the study manuscript

Maryam Hajimoradi, Shadi Shafaghi, Fariba Ghorbani, Hamidreza Jamaati, Fatemeh Sadat Hosseini-Baharanchi, Bahamin Astani, Farnaz Ahmadi, Sima Noorali, Makan Sadr, Fatemeh Nouri, Azadeh Moradkhani

Critical revision for important intellectual content

Hamidreza Jamaati, Maryam Hajimoradi, Fariba Ghorbani, Shadi Shafaghi, Abdolreza Mohamadnia, Seyed Mohsen Zahraei, Farin Rashid Farokhi, Bahamin Astani, Sima Noorali, Farnaz Ahmadi, Seyed MohammadReza Hashemian, Farzaneh Dastan, Payam Tabarsi, Babak Sharif-Kashani, Mostafa Noorizadeh, Mojtaba Nouhi, Seyed MohammadReza Hashemian, Makan Sadr, Majid Marjani, Shahnam Arshi, Fatemeh Nouri, Azadeh Moradkhani

Final approval of the version to be published: All authors

Agreement to be accountable for all aspects of the work: All authors

Reference

1. Chitiga-Mabugu M, Henseler M, Mabugu R, Maisonnave H. Economic and distributional impact of COVID-19: Evidence from macro-micro modelling of the South African economy. *South African Journal of Economics*. 2021;89(1):82-94.
2. WHO COVID-19 Dashboard. Geneva: World Health Organization, 2020. Available online: Published 2020. Accessed April 15, 2023. <https://covid19.who.int/> Title. <https://covid19.who.int/>
3. Nicola M, Alsafi Z, Sohrabi C, et al. The socio-economic implications of the coronavirus pandemic (COVID-19): A review. *International journal of surgery*. 2020;78:185-193.
4. Xiong X, Li J, Huang B, Tam T, Hong Y, Chong K chun. Economic Value of Vaccines to Address the COVID-19 Pandemic in Hong Kong: A Cost-Effectiveness Analysis. 2022;2(March):1-17.
5. Rodrigues CMC, Plotkin SA. Impact of vaccines; health, economic and social perspectives. *Front Microbiol*. 2020;11:1526.
6. Wang Y, Luangasanatip N, Pan W, Juthamas I. Assessing the cost - effectiveness of COVID - 19 vaccines in a low incidence and low mortality setting : the case of Thailand at start of the pandemic Ministry of Public Health National List of Essential Medicines. *The European Journal of Health Economics*. Published online 2022. doi:10.1007/s10198-022-01505-2
7. Marco-Franco JE, Pita-Barros P, González-de-Julián S, Sabat I, Vivas-Consuelo D. Simplified mathematical modelling of uncertainty: Cost-effectiveness of COVID-19 vaccines in Spain. *Mathematics*. 2021;9(5):566.

8. Carvalho N, Jit M, Cox S, Yoong J, Hutubessy RCW. Capturing budget impact considerations within economic evaluations: a systematic review of economic evaluations of rotavirus vaccine in low-and middle-income countries and a proposed assessment framework. *Pharmacoeconomics*. 2018;36:79-90.
9. Bowrin K, Briere JB, Levy P, Millier A, Clay E, Toumi M. Cost-effectiveness analyses using real-world data: an overview of the literature. *J Med Econ*. 2019;22(6):545-553.
10. Pearson CAB, Bozzani F, Procter SR, et al. COVID-19 vaccination in Sindh Province, Pakistan: A modelling study of health impact and cost-effectiveness. *PLoS Med*. 2021;18(10):e1003815. doi:10.1371/journal.pmed.1003815
11. Mauskopf J, Standaert B, Connolly MP, et al. Economic analysis of vaccination programs: an ISPOR good practices for outcomes research task force report. *Value in Health*. 2018;21(10):1133-1149.
12. Wong CKH, Liao Q, Guo VYW, Xin Y, Lam CLK. Cost-effectiveness analysis of vaccinations and decision makings on vaccination programmes in Hong Kong: A systematic review. *Vaccine*. 2017;35(24):3153-3161. doi:10.1016/j.vaccine.2017.04.050
13. Kohli M, Maschio M, Becker D, Weinstein MC. The potential public health and economic value of a hypothetical COVID-19 vaccine in the United States: Use of cost-effectiveness modeling to inform vaccination prioritization. *Vaccine*. 2021;39(7):1157-1164.
14. Li R, Liu H, Fairley CK, et al. Cost-effectiveness analysis of BNT162b2 COVID-19 booster vaccination in the United States. *International Journal of Infectious Diseases*. 2022;119:87-94.
15. Organization WH. Who guide to cost effectiveness analysis. Geneva: World Health Organization, 2003. Published online 2018.
16. Neumann PJ, Sanders GD, Russell LB, Siegel JE, Ganiats TG. *Cost-Effectiveness in Health and Medicine*. Oxford University Press; 2016.
17. Havers FP, Pham H, Taylor CA, et al. COVID-19-associated hospitalizations among vaccinated and unvaccinated adults 18 years or older in 13 US States, January 2021 to April 2022. *JAMA Intern Med*. 2022;182(10):1071-1081.
18. Bartsch SM, Ferguson MC, McKinnell JA, et al. The Potential Health Care Costs And Resource Use Associated With COVID-19 In The United States: A simulation estimate of the direct medical costs and health care resource use associated with COVID-19 infections in the United States. *Health Aff*. 2020;39(6):927-935.

19. Jassat W, Karim SSA, Mudara C, et al. Clinical severity of COVID-19 in patients admitted to hospital during the omicron wave in South Africa: a retrospective observational study. *Lancet Glob Health*. 2022;10(7):e961-e969.
20. Jamaati H, Karimi S, Ghorbani F, et al. Effectiveness of different vaccine platforms in reducing mortality and length of ICU stay in severe and critical cases of COVID-19 in the Omicron variant era: A national cohort study in Iran. *J Med Virol*. 2023;95(3):e28607.
21. Jamaati H, Karimi S, Ghorbani F, et al. Effectiveness of different vaccine platforms in reducing mortality and length of ICU stay in severe and critical cases of COVID-19 in the Omicron variant era: A national cohort study in Iran. *J Med Virol*. 2023;95(3):e28607.
22. Huang Z, Luo J, Li H, et al. Incidence, risk factors, and clinical symptom profile of reinfection during Omicron-dominated COVID-19 outbreak in Hong Kong: A retrospective cohort study. *medRxiv*. Published online 2024:2023-2024.
23. Cai J, Zhang H, Zhu K, et al. Risk of reinfection and severity with the predominant BA. 5 Omicron subvariant China, from December 2022 to January 2023. *Emerg Microbes Infect*. 2024;13(1):2292071.
24. Yang SL, Teh HS, Suah JL, Husin M, Hwong WY. SARS-CoV-2 in Malaysia: A surge of reinfection during the predominantly Omicron period. *The Lancet Regional Health–Western Pacific*. 2022;26.
25. Ukwishaka J, Ndayishimiye Y, Destine E, Danwang C, Kirakoya-Samadoulougou F. Global prevalence of coronavirus disease 2019 reinfection: a systematic review and meta-analysis. *BMC Public Health*. 2023;23(1):778.
26. <https://www.who.int/teams/health-care-readiness/covid-19>.
27. Roser M, Ritchie H, Ortiz-Ospina E, Hasell J. Coronavirus disease (COVID-19)–Statistics and research. *Our World in data*. 2020;4:1-45.
28. Xu S, Li J, Wang H, Wang F, Yin Z, Wang Z. Real-world effectiveness and factors associated with effectiveness of inactivated SARS-CoV-2 vaccines: a systematic review and meta-regression analysis. *BMC Med*. 2023;21(1):1-14.
29. Huang Z, Xu S, Liu J, et al. Effectiveness of inactivated and Ad5-nCoV COVID-19 vaccines against SARS-CoV-2 Omicron BA. 2 variant infection, severe illness, and death. *BMC Med*. 2022;20(1):400.
30. Higdon MM, Wahl B, Jones CB, et al. A Systematic Review of Coronavirus Disease 2019 Vaccine Efficacy and Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Disease. In: *Open Forum Infectious Diseases*. Vol 9. Oxford University Press US; 2022:ofac138.

31. Javanbakht M, Moradi-Lakeh M, Yaghoubi M, et al. Cost-effectiveness analysis of the introduction of rotavirus vaccine in Iran. *Vaccine*. 2015;33:A192-A200.
32. ISNA. Infographic of the prices of some COVID-19 vaccines in Iran and the world. Isna. 2021. <https://www.isna.ir/news/1400063022860/%25D8%25A7%25DB%258>
33. Amar.org.ir. Statistical Center of Iran. doi:<https://amar.org.ir/work#app3050>
34. Emrani Z, Akbari Sari A, Zeraati H, Olyaeemanesh A, Daroudi R. Health-related quality of life measured using the EQ-5D-5 L: population norms for the capital of Iran. *Health Qual Life Outcomes*. 2020;18(1):1-8.
35. Marseille E, Larson B, Kazi DS, Kahn JG, Rosen S. Thresholds for the cost-effectiveness of interventions: alternative approaches. *Bull World Health Organ*. 2015;93(2):118-124. doi:10.2471/BLT.14.138206
36. Moore S, Hill EM, Dyson L, Tildesley MJ, Keeling MJ. Modelling optimal vaccination strategy for SARS-CoV-2 in the UK. *PLoS Comput Biol*. 2021;17(5):e1008849. doi:10.1371/journal.pcbi.1008849
37. Reddy KP, Fitzmaurice KP, Scott JA, et al. Clinical outcomes and cost-effectiveness of COVID-19 vaccination in South Africa. *medRxiv*. Published online November 2021. doi:10.1101/2021.05.07.21256852
38. Moghadas SM, Vilches TN, Zhang K, et al. The Impact of Vaccination on Coronavirus Disease 2019 (COVID-19) Outbreaks in the United States. *Clin Infect Dis*. 2021;73(12):2257-2264. doi:10.1093/cid/ciab079
39. Rasambainarivo F, Ramiadantsoa T, Raherinandrasana A, et al. Prioritizing COVID-19 vaccination efforts and dose allocation within Madagascar. *BMC Public Health*. 2022;22(1):724. doi:10.1186/s12889-022-13150-8
40. Orangi S, Ojal J, Brand SPC, et al. Epidemiological impact and cost-effectiveness analysis of COVID-19 vaccination in Kenya. *BMJ Glob Health*. 2022;7(8):1-13. doi:10.1136/bmjgh-2022-009430
41. Utami AM, Rendrayani F, Suwantika AA. Cost-Effectiveness Analysis of COVID-19 Vaccination in Low- and Middle-Income Countries. 2022;(September):2067-2076.
42. Zhou L, Yan W, Li S. Cost-effectiveness of interventions for the prevention and control of COVID-19 : Systematic review of 85 modelling studies. 2022;12. doi:10.7189/jogh.12.05022
43. Hagens A, İnkaya AÇ, Yildirak K, et al. COVID-19 vaccination scenarios: a cost-effectiveness analysis for Turkey. *Vaccines (Basel)*. 2021;9(4):399.
44. Acharya KP, Ghimire TR, Subramanya SH. Access to and equitable distribution of COVID-19 vaccine in low-income countries. *NPJ Vaccines*. 2021;6(1):54.

45. Jiang Y, Cai D, Shi S. Economic evaluations of inactivated COVID-19 vaccines in six Western Pacific and South East Asian countries and regions : A modeling study. *Infect Dis Model.* 2022;7(1):109-121. doi:10.1016/j.idm.2021.12.002
46. Utami AM, Khoiry QA. Economic evaluation of COVID-19 vaccination : A systematic review. Published online 2023. doi:10.7189/jogh.13.06001
47. Siedner MJ, Alba C, Fitzmaurice KP, et al. Cost-effectiveness of Coronavirus Disease 2019 vaccination in low-and middle-income countries. *J Infect Dis.* 2022;226(11):1887-1896.